[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6017 Introduced in House (IH)]

<DOC>






117th CONGRESS
  1st Session
                                H. R. 6017

 To prohibit certain COVID-19 vaccination mandates for minors, and to 
      require parental consent for COVID-19 vaccination of minors.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           November 18, 2021

Mr. Banks (for himself, Mr. Good of Virginia, Mrs. Cammack, Mrs. Miller 
 of Illinois, Mr. Duncan, Mr. Fallon, Mr. Rouzer, Mr. Murphy of North 
  Carolina, Mr. Bishop of North Carolina, Mr. Jackson, Mr. Allen, Mr. 
 Babin, Mr. Perry, Mr. Posey, Mr. Cawthorn, Mr. Joyce of Pennsylvania, 
Mr. Cline, Mr. Webster of Florida, Mr. Timmons, Mr. Mast, Mr. Aderholt, 
  Mr. Palazzo, Mr. Guest, and Mr. Smith of New Jersey) introduced the 
   following bill; which was referred to the Committee on Energy and 
Commerce, and in addition to the Committee on Education and Labor, for 
a period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL


 
 To prohibit certain COVID-19 vaccination mandates for minors, and to 
      require parental consent for COVID-19 vaccination of minors.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Parental Rights Protection Act''.

SEC. 2. PROHIBITIONS AGAINST COVID-19 VACCINATION MANDATES FOR MINORS.

    (a) Prohibition Against Mandates.--Neither the Federal Government, 
nor any agency, grantee, payee, or recipient, including any State, 
local, Tribal, or territorial governmental entity (including any local 
educational agency, as defined in section 8101 of the Elementary and 
Secondary Education Act of 1965 (20 U.S.C. 7801)), that receives any 
Federal funds from the Department of Education or the Department of 
Health and Human Services may require or otherwise mandate that any 
individual age 18 or younger receive a COVID-19 vaccine.
    (b) Prohibition Against School Mandates.--
            (1) In general.--A local educational agency (as defined in 
        section 8101 of the Elementary and Secondary Education Act of 
        1965 (20 U.S.C. 7801)) that imposes a mandate requiring any 
        students age 18 or younger to receive a COVID-19 vaccine shall 
        be subject to the penalty described in paragraph (2).
            (2) Penalty.--A local educational agency that imposes a 
        mandate described in paragraph (1) shall not be eligible to 
        receive funding under part A of title IV of the Elementary and 
        Secondary Education Act of 1965 (20 U.S.C. 7101 et seq.) or 
        under part A of title II of such Act (20 U.S.C. 6611 et seq.) 
        beginning on the later of--
                    (A) the date of enactment of this Act; or
                    (B) the date on which such mandate becomes 
                effective.
            (3) Resumed eligibility.--If a local educational agency 
        ends the mandate described in paragraph (1) that local 
        educational agency shall become eligible to receive the funding 
        described in paragraph (2) as of the date on which that mandate 
        is no longer effective.

SEC. 3. PARENTAL CONSENT FOR VACCINATION OF MINORS.

    No COVID-19 vaccine may be administered to any individual age 18 or 
younger unless a parent, guardian, conservator, or attorney-in-fact of 
the minor provides prior, written, informed consent for the minor to 
receive such vaccine.

SEC. 4. APPLICABLE VACCINES.

    For purposes of sections 2 and 3, the term ``COVID-19 vaccine'' 
means any vaccine against COVID-19 that only received authorization by 
the Food and Drug Administration through an emergency use authorization 
pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360bbb-3), or that has received such authorization prior to 
receiving full approval or licensure under section 505 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of the 
Public Health Service Act (42 U.S.C. 262).
                                 <all>